Entocort EC, a new ORAL form of budesonide for Crohn's disease
November 2001
AstraZeneca will soon introduce Entocort EC, a new ORAL form of budesonide for Crohn's disease.
It's approved for acute flare-ups that involve the ileum and/or ascending colon...it's not approved for chronic use.
Entocort EC releases budesonide in the small intestine and colon to decrease inflammation.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote